The cannabinoid receptor 1 (CB1), a member of the class A G-protein-coupled receptor (GPCR) family, possesses an observable level of constitutive activity. Its activation mechanism, however, has yet to be elucidated. Previously we discovered dramatic changes in CB1 activity due to single mutations; T3.46A, which made the receptor inactive, and T3.46I and L3.43A, which made it essentially fully constitutively active. Our subsequent prediction of the structures of these mutant receptors indicated that these changes in activity are explained in terms of the pattern of saltbridges in the receptor region involving transmembrane domains 2, 3, 5, and 6. Here we identified key salt-bridges, R2.37 + D6.30 and D2.63 + K3.28, critical for CB1 inactive and active states, respectively, and generated new mutant receptors that we predicted would change CB1 activity by either precluding or promoting these interactions. We find that breaking the R2.37 + D6.30 saltbridge resulted in substantial increase in G-protein coupling activity and reduced thermal stability relative to the wild-type reflecting the changes in constitutive activity from inactive to active. In contrast, breaking the D2.63 + K3.28 salt-bridge produced the opposite profile suggesting this interaction is critical for the receptor activation. Thus, we demonstrate an excellent correlation with the predicted pattern of key salt-bridges and experimental levels of activity and conformational flexibility. These results are also consistent with the extended ternary complex model with respect to shifts in agonist and inverse agonist affinity and provide a powerful framework for understanding the molecular basis for the multiple stages of CB1 activation and that of other GPCRs in general.
INTRODUCTION
G protein-coupled receptors (GPCRs) play a central role in biological processes by transmitting signals from various external stimuli, including neurotransmitters, hormones, and light, across the cell membrane. The cannabinoid receptor one (CB1) is a member of the rhodopsin-like GPCR family that binds Δ 9 -THC, the psychoactive component of marijuana, and exerts its pharmacological effects via intracellular signaling cascades. CB1 is one of the most abundant GPCRs in the mammalian brain and is found in the basal ganglia, cerebellum, and hippocampus. Like other GPCRs, activation by agonists, induces CB1 to undergo conformational changes that promote activation of the coupled guanine nucleotidebinding protein (G-protein) which then stimulates downstream effector proteins, such as inhibition of adenylate cyclase activity and calcium channels and activation of inwardly rectifying potassium channels. 1 Early thinking about GPCR function assumed the existence of just two GPCR states, the "off" (R) and "on" (R*) modes representing the inactive and active states of the receptor, respectively. 2 This binary complex model suggests that an agonist shifts the equilibrium in favor of the active form of the receptor that can couple to G-protein. This model was later extended to account for the activity of constitutively active mutant (CAM) receptors that can couple to G-protein in a ligand-independent manner. 3, 4 Since CAMs are pre-coupled to G protein, they are characterized by enhanced affinity for agonists, decreased affinity for inverse agonists, and increased basal functional activity. Interestingly, CAMs are known for many GPCRs, including rhodopsin, 5 β 1 adrenergic receptor, 6 histamine H1 receptor, 7 angiotensin receptor type 1, 8 opioid receptor, 9 and the CB1 cannabinoid receptor. 10, 11 More recently it has become clear that GPCRs can adopt multiple distinct conformations displaying different states of receptor activation resulting in different signaling efficacies. 12 Thus, the transition from inactive to active forms of a GPCR may include several distinct conformational substates that can be differentially stabilized by G proteins or by different ligands -opening the way for highly selective therapeutic agents-or by mutations that stabilize a particular receptor conformation. [13] [14] [15] Many GPCRs 16, 17 including the CB1 receptor 18 possess constitutive activity in the absence of ligand. Therefore, wild-type CB1 is at a pivot point and can become more fully activated by agonists such as CP55940 and Δ 9 -THC or inhibited by the inverse agonists SR141716A and AM251. 19 Using the wild-type and mutant forms of the CB1 receptor, this study presents for the first time a detailed activation mechanism that provides a structural basis for the constitutive activity exhibited by GPCRs, how they become fully inactive, and what structural changes allow them to become more active.
We previously showed that the single amino acid substitution of leucine at position 3.43 with alanine, or of threonine 3.46 with isoleucine, caused the slightly active CB1 receptor to become highly constitutively active. 10, 11 Note the positions of the transmembrane (TM) helix residues are indicated using the Ballesteros-Weinstein amino acid numbering system 20 throughout the text. In this numbering system, the most conserved residue in each TM helix is given the location of 0.50. This number is preceded by the TM number. All other residues in the TM helix are numbered relative to this residue. Thus, the L3. 43 and T3. 46 residues are approximately two and one turn above, respectively, the arginine residue of the highly conserved DRY motif in TM3, which has been shown to form ionic interactions with the glutamic acid residues at position 3.49 and 6.30 in the crystal structure of inactive rhodopsin. 21 In contrast, we showed that an alanine substitution of T3.46 resulted in a fully inactive receptor. Consistent with the characteristics of a CAM, the more active T3.46I and L3.43A receptors show enhanced and decreased affinities for agonists and inverse agonists, respectively, relative to the wild-type receptor while the inactive T3.46A receptor exhibits the reverse profile.
To interpret the dramatic changes in function observed for the wild-type, L3.43A, T3.46A, and T3.46I receptors, we used the GEnSeMBLE (GPCR Ensemble of Structures in Membrane Bilayer Environment) method 22 to predict the three-dimensional structures of their TM domains and found that their stability and activity correlates with the predicted pattern of key salt-bridges. 23 Our previous study shows that the differences between the active and inactive predicted structures agree well with those observed between active and inactive crystallographically characterized GPCRs, 21, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] giving credence to the predicted structures. While many diverse types of contacts and interhelical interactions stabilize each activation state, our work focuses on the salt-bridges, especially the intracellular ones. Changes in hydrophobic interactions, aromatic stacking, and hydrogen bonds in the TM bundle are important, but they do not provide the strongest indication for activation.
Our computational predictions of CB1 suggest that transition between distinct patterns of salt-bridges is critical for receptor activity. Based on these predicted structures and the hypothesis that the salt-bridges control the propensity for activation, we predicted a series of new CB1 mutants expected to either preclude or promote these ionic interactions which we expected to exhibit specific levels of constitutive activity relative to the wild-type receptor. Indeed, our computational structural prediction data showed the pattern of key salt-bridges is conserved among the mutant receptors that are expected to have a similar level of constitutive activity suggesting those may be critical for receptor activation. In particular, the R2.37 + D6.30 and D2.63 + K3.28 salt-bridges are identified in inactive and active CB1 receptors, respectively. We then experimentally constructed these mutants to break these salt-bridges and found that they exhibit substantial shifts in G protein coupling, thermal stability, and ligand binding affinity relative to the wild-type, consistent with our expected changes in constitutive activity and conformational flexibility. This excellent correlation of experimental activation propensity with the role of key salt-bridges in our predicted structures provides new insight into the interconnection between structure and function of CB1. These results support and extend the concepts of the extended ternary complex model with respect to shifts in agonist and inverse agonist affinity. 6, 39, 40 This provides a new powerful framework for understanding the molecular basis for the stages of CB1 activation in particular and by inference that of other GPCRs.
MATERIALS AND METHODS
force field. 41 The ensemble of the best 10 conformations (by lowest energy) for each mutant was analyzed in detail for the presence of salt-bridge, hydrogen-bond, and hydrophobic interactions. Briefly, the seven individual TMs were predicted based on the octanol hydrophobicity scale 42 using the PredicTM 22 method and extended using helical structure predictions from three secondary structure prediction servers: Porter Protein Secondary Structure Prediction Server, 43, 44 APSSP2: Advanced Protein Secondary Structure Prediction Server, 45, 46 and PSIPRED: Protein Prediction Server. [47] [48] [49] The separate helices were built and optimized with OptHelix 22 before the TMs aligned to multiple crystal templates. We compared the energies resulting from the turkey beta 1 adrenergic receptor, bovine rhodopsin receptor, human β 2 adrenergic receptor, and human adenosine A 2A receptor templates because they were the only crystallographically characterized GPCRs available at the time of these computational studies. The turkey β 1 adrenergic receptor crystal provided the lowest energy helix packing conformations for the wild-type CB1 receptor, which is a reasonable result because out of the four receptors, the turkey β 1 adrenergic receptor had the highest percentage identity of conserved TM residues with respect to the CB1 wild-type receptor at 28.45%. We completed the following procedure with this template.
To predict the structures of single and double mutant receptors, the target residues were mutated in the OptHelix optimized TM2 or TM3 from the wild-type receptor using SCREAM (Side Chain Rotamer Excitation Analysis Method). 50 Each helix rotation angle (η) was sampled using the BiHelix method, 51 where the side chain rotamers were optimized using SCREAM. For the lowest energy conformation from the BiHelix protocol, we performed a local sampling of helix tilt angle (θ), sweep angle (φ), and rotation angle (η) for all pairs of interacting helices while optimizing the side chain rotamers using SCREAM. From this, the top 2000 conformations were selected and reordered using more accurate conformational energies obtained by explicitly constructing the 7-helix bundles. Each of them was minimized for 10 steps in a vacuum. Finally, the 10 lowest energy structures were selected according to the average energy rank. Four different types of energies were calculated for each minimized receptor including the charged total energy, the neutralized total energy, the charged interhelical energy, and the neutralized interhelical energy. The total energy refers to the energy of the entire receptor, whereas the interhelical energy is defined as the energy between interacting helices. In the charged state, the acidic residues (glutamic acid and aspartic acid) have a negative charge, and the basic residues (lysine, protonated histidine, and arginine) have a positive one. Under the neutralized conditions, the acidic residues gain a hydrogen atom and the basic residues lose one. Each receptor is ranked according to these four energy types, and these respective ranks are averaged to give a final rank representing the average energy rank. We examined a small selection of 10 final receptor conformations. These 10 receptors are found to all share similar characteristics, which define the "consensus structure." The receptor conformations shown in Figure 1 (A) are those that faithfully represent the consensus structure.
CB1 expression and membrane preparation
The plasmid DNA encoding human CB1 receptors was prepared as previously described. 52 HEK293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 3.5 mg/mL glucose at 37°C in 5% CO 2 . For transient expression of the receptors, HEK293 cells were seeded at 1 million cells/100 mm dish on the day prior to transfection using the calcium phosphate precipitation method. 53 Twenty-four hours posttransfection, membranes of transfected cells expressing the wild-type or mutant receptors were prepared using nitrogen cavitation as previously described. 10 
GTPγS binding assay
Approximately 5 μg of membrane preparations from HEK293 cells expressing CB1 receptors were incubated for 60 min at 30°C in a total volume of 500 μL GTPγS binding assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl 2 , 0.2 mM EGTA, and 100 mM NaCl) with 0.1 nM [ 35 S]GTPγS (1250 Ci/mmol, PerkinElmer Life Sciences, Boston, MA), 1 μM GDP, and 0.1% (w/v) BSA. The levels of basal and CP55940-induced GTPγS binding were measured in the absence of ligand and presence of 1 μM unlabeled CP55940, respectively. Non-specific binding was determined with 10 μM unlabeled GTPγS (Sigma, St Louis, MO). The reaction was terminated by rapid filtration to separate the membrane-bound fraction from the free through Whatman GF/C filters (Brandel Inc., Gaithersburg, MD). The radioactivity of the membrane-bound [ 35 S]GTPγS trapped in the filters was determined by liquid scintillation counting. Pilot experiments were conducted to ensure that there is no depletion of ligand, nucleotides, and G proteins in the assay system.
Measurement of receptor thermal stability
A previously established method for determining receptor stability as a function of temperature in the absence of ligand was employed. 54, 55 Approximately 5 μg of membrane preparations from the CB1 receptor-expressing HEK293 cells were incubated at the specified temperature for 30 min in the absence of ligand. Control samples for each receptor were kept on ice for 30 min. For every mutant, the different membrane aliquots were each heated at a single temperature ranging from 30°C to 100°C. After incubation, the samples were quenched on ice, re-homogenized, and added to TME buffer containing a nearsaturating concentration of [ 3 H]CP55940 (147.9 Ci/mmol, PerkinElmer Life Sciences, Boston, MA) for further incubation for 60 min at 30°C. The radiolabeled-ligand was used at a concentration 10-fold above K d for each receptor as determined by saturation binding, 56 to minimize the impact of any possible affinity change due to heat treatment. Nonspecific binding was determined in the presence of 1 μM unlabeled ligand. Reactions were terminated by filtration with a Brandel cell harvester through Whatman GF/C filter paper. Radioactivity was measured by liquid scintillation counting. Three independent thermal stability measurements were carried out each in duplicate. The data were analyzed by nonlinear regression using GraphPad Prism Software (GraphPad Software Inc., San Diego, CA) to obtain the slope and midpoint (apparent T m ) at 50% loss of specific binding as described previously. 54, 55 Radioligand binding assay Saturation binding assays were performed as previously described. 56 Briefly, approximately 5 μg of membranes were incubated at 30°C for 60 min with [ 3 H]CP55940 (147.9 Ci/mmol, PerkinElmer Life Sciences, Boston, MA) or [ 3 H]SR141716A (43 Ci/mmol, PerkinElmer Life Sciences, Boston, MA) in a total volume of 200 μL or 500 μL TME buffer (25 mM Tris-HCl, 5mM MgCl 2 , and 1 mM EDTA, pH 7.4) containing 0.1% fatty acid-free bovine serum albumin. At least nine radiolabeled-ligand concentrations were used to determine K d values of the receptors. Nonspecific binding was determined in the presence of 1 μM of unlabeled ligand. Reactions were terminated by filtration with a Brandel cell harvester through Whatman GF/C filter paper followed by four washes with ice-cold TME buffer to remove unbound radioactivity. Radioactivity was measured by liquid scintillation counting.
Data analysis
All data points represent the mean ± SE of at least three independent experiments performed in duplicate. For saturation radioligand binding assay, the K d and B max values were calculated by nonlinear regression using GraphPad Prism Software (GraphPad Software Inc., San Diego, CA). The values for the wild-type and mutant receptors were compared using analysis of variance (ANOVA) followed by Bonferroni's post hoc test for significance. P values of <0.05 were considered to be statistically significant.
RESULTS

Predicting interactions key to CB1 receptor activation
We previously demonstrated experimentally that the amino acids at position T3.46 and L3.43 are key to receptor activation. 10, 11 Mutating T3.46 to isoleucine or L3.43 to alanine yielded highly constitutively active receptors, while replacing T3.46 with alanine inactivated the constitutively active wild-type CB1 receptor. To identify a structural basis for these experimental results, we predicted the ensemble of energetically favorable conformations for the wild-type, L3.43A, T3.46I, and T3.46A receptors using the first-principles-based GEnSeMBLE method. 22 Figure 1(A) shows the predicted structures of these receptors in terms of the key salt-bridges. We also found some differences in aromatic residue interactions and in hydrogen bonding interactions, however, we consider these changes to be less important in explaining the dramatic change from inactive to active structures.
The wild-type CB1 receptor is unique from other GPCRs because it has a threonine residue (T3.46) one turn above the conserved R3.50. In other GPCRs, this residue is either an alanine or a leucine. Our computational predictions indicate that CB1 contains a unique hydrogen bond involving T3.46 and S2.45. The S2.45 residue usually participates in the highly conserved 2-3-4 hydrogen bond network as observed in other crystallized GPCRs. By mutating T3.46 to alanine or leucine, we break this hydrogen bond connecting TM2 and 3, as seen in Figure 1 (A.2). In the T3.46I mutant, the larger hydrophobic isoleucine side-chain pushes the surrounding helices, including TM6, away in order to provide enough room to avoid side-chain clashes. In the T3.46A mutant, the alanine residue is smaller than threonine and can fit in-between TMs 2 and 6. These two helices do not have to be as far away to avoid clashes as they would in the wild-type or T3.46I receptors. The T3.46A residue, however, does not interact with S2.45, so TM2 is rotated to optimize other polar interactions. In the L3.43A mutant, the threonine residue is left intact and thus so is the S2.45 and T3.46 hydrogen bond. The position of TM6 in relation to TM3 can change because the new alanine residue takes up less space than the original leucine one. The residues in the middle of TM6, such as V6.43, would clash with the 3.43 residue if the WT sequence had the L3.43A mutant conformation. In the L3.43A mutant, the extracellular end tilts towards TM3, but the intracellular end moves away breaking the R3.50 + D6.30 interaction.
A comparison of the Cα-RMSD measure for the TM region across three of the functionally distinct structures, WT, T3.46A, and T3.46I, shows it to be 2.54 Å for the WT-T3.46A pair, 2.12 Å for the WT-T3.46I pair, and 2.86 Å for the T3.46A-T3.46I pair. A comparison of these numbers for the GPCRs crystallized in at least two distinct conformations was done. This Cα-RMSD measure for the common TM region for human β2 adrenergic receptor in the inactive (PDB ID: 2RH1) and the active (PDB ID: 3SN6) forms is: 2.48 Å. This measure for rhodopsin (PDB ID: 1U19) and metarhodopsin II (PDB ID: 3PQR) is 2.34 Å. For the adenosine A 2A receptor, the partially active form (PDB ID: 3QAK) deviates from the inactive form (PDB ID: 3EML) by 1.61 Å. The observed structural changes in the CB1 receptor in different functional forms are comparable in magnitude with that observed in the crystallized GPCRs. The smaller inactive-to-active deviation in the A 2A receptor is a manifestation of the fact that the active receptor is only partially active and cannot yet accommodate a G protein.
Comparing the predicted conformations for T3.46A, wild-type, T3.46I, and L3.43A, we found excellent correlation of the salt-bridge patterns with the experimentally determined extent of receptor activation (e.g. inactive, partially and fully active receptors) as summarized in Figure 1 (B). We found that (1) only the fully inactive receptor has an R2.37 + D6.30 salt-bridge; note, the salt-bridge and hydrogen bond interactions are indicated by a plus (+) and a dash (-), respectively, throughout the text. At the other end of the spectrum, the D2.63 + K3.28 salt-bridge is required for full receptor activity (as in L3.43A and T3.46I) and it may be accompanied by a R5.71 + D6.30 salt-bridge (found in T3.46I) but this is not necessary for activation. However, when the D2.63 + K3.28 salt-bridge is accompanied by the R3.50 + D6.30 and D3.49 + K4.41 salt-bridges, they constrain the receptor to a less active state, and thus although the wild-type receptor also has this salt-bridge, it is only weakly active. These interpretations are consistent with the occurrence of this R3.50 + D6.30 salt-bridge between the DRY motif in TM3 and the D/E residue on the cytoplasmic side of TM6 in many GPCRs believed to be important for stabilizing the receptor inactive conformation. 57, 58 To evaluate the significance of these non-covalent interactions in receptor activation, we proceeded to predict a series of receptors with single and double point mutations which by the above concepts were expected to have specific changes in their activity and then experimentally tested their biochemical properties. The predicted structures highlighting the amino acids mutated, the R2.37 and D2.63 residues in TM2 and the L3.43 and T3.46 in TM3, are shown in Figure 2 (A). Figure 2( 28 . These include the R2.37Q/T3.46A, R2.37A/T3.46A, and D2.63A/L3.43A receptors. Given the pattern of saltbridges identified in the consensus structures, these receptors are grouped by their expected levels of constitutive activity (e.g. highly active, partially active, or inactive). Figure 2 (C) shows a full list of the CB1 receptors generated in this study in terms of predicted extent of constitutive activity. These include the L3.43A/T3.46I, L3.43A/T3.46A, and R2.37A/ D2.63A/L3.43A receptors in addition to the receptors shown in Figure 2(B) . We expect the L3.43A/T3.46I receptor to display a level of constitutive activity comparable to or higher than that of the L3.43A or the T3.46I receptor alone, since the individual mutations both lead to high constitutive activity. In contrast, the L3.43A/T3.46A mutant receptor is expected to possess somewhat reduced constitutive activity relative to the L3.43A mutation alone since it is combined with the inactivating alanine substitution at position T3.46. 10 Since our structure prediction indicates the salt-bridge between R2.37 and D6.30 is critical for maintaining the T3.46A receptor inactive, we expect that two mutant receptors, R2.37A/ T3.46A and R2.37Q/T3.46A, will break the salt-bridge between R2.37 and D6.30. The D2.63A/L3.43A receptor was also constructed and cannot form the activating D2.63 + K3.28 salt-bridge. Interestingly, computational analysis indicates that this mutant receptor adopts the inactivating R2.37 + D6.30 salt-bridge. Thus, we expect breaking the resulting R2.37 + D6.30 salt-bridge in the D2.63A/L3.43A receptor would result in regaining of some constitutive activity. This is further tested by characterizing the triple mutant, R2.37A/ D2.63A/L3.43A. Collectively, we hypothesized that the R2.37 + D6.30 and D2.63 + K3.28 salt-bridges may be critical for inactive and constitutively active conformations, respectively; however, if the latter is accompanied by a D3.49 + K4.41 and/or a R3.50 + D6.30 saltbridge, like the wild-type, full receptor activity cannot be obtained. Some residues identified in Figure 1 (B) (D3.49 and D6.30) have been excluded from this mutational study because they appear to be involved in multiple interactions making it difficult to interpret the data. Moreover, our predictions and others 57, 59, 60 suggested that they (as well as K3.28 and K4.41) may have a secondary role in receptor assembly and/or ligand interactions in addition to activation. The R5.71 + D6.30 salt-bridge has also been omitted in this study because this is present in the T3.46I receptor, but not in the L3.43A receptor, suggesting this interaction is not essential for receptor activation. The resulting mutant receptors were then evaluated for their biochemical properties to ascertain the extent to which receptor activity could be correlated with the non-covalent interactions identified.
Basal [ 35 S]GTPγS binding reveals the level of constitutive activity of the CB1 receptors
To measure directly the functional activity of the receptors, we investigated [ 35 
which is comparable to the level of a mock-transfected sample (53.2 fmol/mg) [ Fig. 3(A) ]. Thus, the residual activity observed by us (~ 53 fmol/mg) and others 62, 63 is non-CB1 mediated and those receptors are in the fully inactive state. Two double mutants, the R2.37Q/T3.46A and R2.37A/T3.46A receptors, regained some constitutive activity, evidenced by the level of GTPγS binding of 77.0 fmol/mg and 72.5 fmol/mg, respectively. Interestingly, the triple mutant R2.37A/D2.63A/L3.43A also exhibited some level of constitutive activity (68.1 fmol/mg). Although these two double mutants and triple mutant displayed less constitutive activity than the wild-type (98.5 fmol/mg), the level is nonetheless remarkable; the data suggest that the salt-bridge involving the arginine at position 2.37 may be critical for the inactive conformation and when this interaction breaks, some constitutive activity is regained. The levels of GTPγS binding are only marginally different between the L3.43A/T3.46A and wild-type receptors. The L3.43A and T3.46I, and L3.43A/T3.46I receptors displayed the greatest constitutive activity with a similar level of GTPγS binding (112.3 fmol/mg, 114.5 fmol/mg, and 121.5 fmol/mg, respectively). Taken together, the experimentally measured levels of basal activity for the CB1 mutant receptors agree exceedingly well with the computationally predicted patterns of ionic interactions [Figs. 2(C) and 3(A)].
CP55940-stimulated [ 35 S]GTPγS binding suggests the maximal level of possible G protein coupling
To further evaluate how agonists impact the activity of the receptors, we investigated the agonist-promoted [ 35 S]GTPγS binding to membranes expressing the CB1 receptors. Figure  3 It is important to note that 1 μM CP55940 treatment induced little to no increase of GTPγS binding relative to the basal level for the L3.43A, T3.46I, and L3.43A/ T3.46I receptors, suggesting these receptors may already adopt an active conformation comparable to a fully active receptor even in the absence of agonists. Intriguingly, although two inactive mutant receptors, D2.63A/L3.43A and T3.46A displayed a significant increase in GTPγS binding with 1 μM CP55940, the levels were significantly lower than that of the wild-type [ Fig. 3(B) ]. This suggests that these inactive mutants are not able to be fully activated either because of a lack of particular non-covalent interactions critical for full receptor activation or because of the existence of a remaining constraint such as the TM2 + TM6 or TM3 + TM6 coupling that stabilizes the inactive state even upon CP55940 binding. Although the R2.37A/D2.63A/L3.43A receptor regained some constitutive activity in the absence of ligand, it was not fully activated by CP55940 suggesting the important role of the D2.63 residue in full receptor activation. Note that CP55940 treatment showed no change in the mock-transfected sample indicating that the CP55940-induced [ 35 S]GTPγS is CB1 receptor-mediated.
Thermal stabilities of the CB1 receptors are consistent with a spectrum of active states
It is generally accepted that the active conformation in its apo form is less stable relative to the inactive conformation. 64 Indeed, CAMs of many GPCRs have been shown to adopt the conformation having increased flexibility with marked instability. 64, 65 To obtain an experimental measurement of the relative stability of the CB1 receptors, we preformed thermal denaturation assays in the absence of ligand as previously established by many groups. 54, 55 The term "stability" used in this study is defined as the ability of the receptor to maintain a correctly folded state, especially within its binding pocket believed to form within the helical bundle. Since the wild-type receptor has been shown to possess significant constitutive activity, 18, 66 it can become either inactive or fully active, and consequently its temperature midpoint of the denaturation curve, T m, should vary accordingly with the mutations described. As shown in Figure 4 (A) and Table I Table I ]. Our data also indicates that the inactive receptors, T3.46A and D2.63A/ L3.43A, adopted the most stable conformation among the receptors we tested, indicated by their T m (71.4 ± 1.8°C and 72.1 ± 2.1°C, respectively). Taken together with the basal G protein coupling data, we demonstrate that in the absence of ligand, the single and double mutations on TM2 and TM3 progressively impact the receptor's thermal stability correlating well with predicted conformational changes, and in turn changes in the equilibrium between the inactive (R) and highly active receptor (R*). Figure 4 (C) shows an excellent correlation between the T m and the receptor activity level determined from GTPγS binding with an R 2 value of 0.9722. This indicates that the conformational change adopted by these mutants results in a corresponding functional change, as the receptor becomes thermodynamically less stable with increasing activity.
4(B) and
Ligand binding affinity reflects extent of basal activity
One of the remarkable characteristics of CAMs is that their ligand binding affinity shifts due to pre-coupling to the G protein. In general, CAMs are characterized by enhanced affinity for agonists and decreased affinity for inverse agonists, whereas inactive GPCRs exhibit the opposite characteristics; decreased affinity for agonists and enhanced affinity for inverse agonist. 6, 39, 40 To evaluate the predicted correlations between the key intramolecular interactions of the receptor with ligand binding profiles and consequently test the predictions of the extended ternary complex model on the series of mutant receptors shown in Figure  2 (B), we carried out saturation binding experiments using the CB1 agonist (Table II) . The inactive mutant receptor T3.46A displays a sixfold reduced affinity for CP55940 compared to the wild-type receptor with a K d value of 9.83 ± 1.12 nM. This is consistent with our previous homologous competition binding data for these receptors. 10, 11 As predicted, the L3.43A/T3.46I receptor exhibits a K d value (0.28 ± 0.02 nM) comparable to the individual single mutant receptors, L3.43A and T3.46I, whereas the L3.43A/T3.46A showed a wild-type-like affinity for CP55940 with K d of 1.10 ± 0.23 nM.
Since the salt-bridge between R2.37 and D6.30 cannot form in the R2.37A/T3.46A, R2.37Q/ T3.46A, and R2.37A/D2.63A/L3.43A receptors, these receptors exhibited ligand binding affinity profiles between those of the T3.46A and wild-type receptors with K d values of 5.58 ± 0.32 nM, 6.21 ± 1.11 nM, and 7.63 ± 0.89, respectively, confirming that the R2.37 is critical for the CB1 inactive conformation.
In order to evaluate the importance of D2.63 on the transition to an active conformation, we considered the D2.63A/L3.43A mutant, which was predicted to be inactive. Indeed, this mutant receptor showed a markedly decreased affinity for CP55940 with a K d of 12.74 ± 2.13 nM, which is comparable to the inactive T3.46A receptor, confirming the theoretical prediction that D2.63 is required for activation of this receptor. No significant differences were observed between the B max values of any of the mutant receptors tested.
In accordance with the extended ternary complex model, 3 agonists shift the equilibrium toward a state where active receptors (R*) predominate, whereas inverse agonists increase the inactive receptor (R) population. Therefore, this model predicts that constitutively active receptors possess increased affinity for agonist, as we demonstrated with CP55940. The affinity changes of CB1 receptors with single and double mutations for the agonist CP55940 inspired us to also assess the effect of the mutations on the affinity for inverse agonist using (Table II) . Thus, the GTPγS data, thermal stability, and ligand binding properties demonstrate that the single and double mutations on TM2 and TM3 impact the receptor's functional activity, providing an array of constitutive activity from the inactive (R) to highly active receptor states (R*).
DISCUSSION
A central question driving GPCR structural studies involves how the individual TMs move and interact during activation and how this rearrangement affects their interactions with downstream signaling molecules, such as G-proteins, β-arrestins, and G-protein coupled receptor kinases. To address this fundamental question, we predicted the CB1 receptor structures for the wild-type and several mutants and found systematic differences of specific inter-helical interactions critical to different levels of receptor activation. We observed shifts in G-protein coupling activity, receptor stability, and ligand binding affinity consistent with our computational predictions. Consequently, we have generated a collection of CB1 receptors involving minimal modifications that collectively exhibit a continuum of constitutive activity. These include two mutant receptors, D2.63A/L3.43A and T3.46A, that we predicted would be inactive and which subsequent experiments, indeed, showed to display inactive receptor properties. These involved mutations that lead to functions opposite of those exhibited by CAMs. The properties of the D2.63A/L3.43A receptor are particularly remarkable because computational analysis indicates that it adopts the inactivating R2.37 + D6.30 salt-bridge while experiments show the profiles corresponding to an inactive receptor (Table II) ; this mutant receptor cannot form the D2.63 + K3.28 activating salt-bridge and thus is inactive despite the inclusion of the L3.43A mutation. It is important to note that we included only one residue of each of the two salt bridges (e.g. D2.63 and R2.37) for mutational study, since each respective partners (D6.30 and K3.28, respectively) is likely involved in multiple interactions critical for receptor activation and ligand binding. 59, 60, 67, 68 Therefore, our mutational study does not firmly rule out the possibility that the salt-bridges did not involve the D6.30 and K3.28 residues. However, the computationally predicted formation of the R2.37 + D6.30 salt-bridge in the D2.63A/L3.43A receptor was tested by the triple mutant, D2.63A/L3.43A/R2.37A (Figs. 3 and 4 , Tables I and II) , and the data further support that the R2.37 residue is critical for receptor activity likely through interaction with D6.30. We predict that a similar salt-bridge pattern can be achieved for more than a single CAM. For example, we demonstrated that both T3.46I and L3.43A are highly constitutively active and share key salt-bridge interactions, such as the D2.63 + K3.28 [ Fig. 1(B) ]. Similarly, two inactive mutants T3.46A and D2.63A/L3.43A retained the TM2 + TM6 lock. Thus, our proposed activation mechanism reveals key global interactions responsible for receptor activation rather than specific local interaction changes. Given that GPCRs can adopt multiple activation states, our activation mechanism provides a structural template that can be expanded further to test for other CAMs. Since the first CAM was generated for the α 1B -adrenergic receptor leading to spontaneous G-protein activation in the absence of an agonist, 6,69 single amino acid substitutions in various regions of different GPCRs have been shown to produce enhanced constitutive activity. 70, 71 These regions include the cytoplasmic extensions of TMs 2, 3, 6, and 7, indicating that these are sensitive to receptor activity. Intriguingly, recent studies demonstrate that mutations on the extracellular loops 2 and 3 can also result in enhanced constitutive activity in the C5a and adenosine A2b receptors. 72, 73 Molecular modeling data suggest that some mutations on the extracellular loops alter the interactions between the loops and TMs, which in turn impact the TM helix packing arrangement involving TMs 2, 3, and 7. 72 In addition to the crystal structures of inactive GPCRs, a few GPCRs have been recently crystallized in the active conformation including rhodopsin, the β 2 -adrenergic receptor and the A 2A adenosine receptor. 25, [74] [75] [76] [77] These active state structures reveal some common patterns of conformational changes providing snapshots of the "active" forms. For example, metarhodopsin II, Gs-bound β2-adrenergic receptors, and the A 2A adenosine receptor displayed significant conformational changes due to alteration of the inter-helical hydrogen bond network involving residues in TMs 3, 5, 6 and 7 near the ligand binding pocket. 75, 77, 78 This suggests that although the residues interacting with agonists are largely receptor specific, they seem to undergo a similar conformational change via these TMs upon activation. A similar pattern of TM movement upon activation was observed in our predicted CB1 structures. 23 In addition, the "active" forms exhibit a rearrangement (tilting and rotation) of TM6 and neutralization of D3.49 in the DRY motif of TM3. Those adjustments allow for accommodation of the G-protein at the cytoplasmic side of the receptors. 25, 74, 76, 77 Our predicted receptor conformations are consistent with this, indicating that CB1 also undergoes a similar activation mechanism involving TM6 and TM3. However, our data also indicate the existence of a TM2 + TM6 salt-bridge in the inactive conformation, which is unique to the CB1 receptor and points to an additional element in its mechanism of activation. Breaking the R2.37 + D6.30 and forming the D2.63 + K3.28 salt-bridge are critical for constitutive activity.
In addition to disruption of key salt-bridges, 79, 80 our paradigm for GPCR activation involves rigid body movement of the TMs due to changes in the hydrogen bonding network 81, 82 and aromatic residue interactions. 83, 84 For example, our predicted structures contain multiple hydrogen bonds involving TM2 and TM4 that have also been found in the crystallized GPCRs. 21, 25, [85] [86] [87] We predict a H2.41-K4.41 hydrogen bond in the wild-type receptor and a Y2.40-R4.39 hydrogen bond in both wild-type and T3.46I mutant receptors. A Y2.41-K4. 43 hydrogen bond has been observed experimentally in the inactive human A2A adenosine receptor structure, 85 and a Y2.41-E4.39 hydrogen bond has been observed in multiple crystal structures including bovine rhodopsin, 21 the active opsin, 86, 87 and the active meta II. 25 However, since the presence of these non-covalent interactions varies among different receptor states, our computational predictions strongly suggest that intracellular ionic interactions are the driving force leading to the dramatic changes in activity among the receptors we tested. This is consistent with MD simulations on the β2 adrenergic receptor. 88 It is well accepted that high constitutive activity requires the absence of intramolecular interactions that constrain the receptor in the R state. 89 Our proposed helix packing pattern shows that the highly constitutively active mutant receptors, L3.43A/T3.46I, L3.43A, and T3.46I lack the intracellular ionic coupling across TMs, such as the most conserved TM3 + TM6 ionic lock and the TM2 + TM6 salt-bridge are present in the inactive form of CB1. Instead, the active receptors seem to possess salt-bridge interactions between neighboring TMs (e.g. TM2 + TM3 and TM5 + TM6) resulting in a larger diameter (11.64 Å) at the cytoplasmic end of TM3 and TM6 than that of the T3.46A (8.47 Å) or wild-type (8.93 Å) receptors. This conformational change may facilitate accommodation of the C-terminal α-helix of the G α protein during receptor activation. 87 The lack of the constraining salt-bridges that are present in the inactive mutants and slightly active wild-type receptor allows the CAM receptors to relax into the R* conformation and the transition to this conformation results in enhanced conformational flexibility and lower stability. To measure the structural stability of GPCRs, a thermal stability measurement was developed for GPCRs by many groups. 55, 64 Initially, GPCR thermal stability was measured to screen for more stable conformations for structural analysis such as X-ray crystallography. 90, 91 We applied these measurements to each receptor to evaluate the correlation between receptor activity and conformational instability in the absence of ligand during the denaturing step (heat treatment) at various temperatures and subsequently determined the stability by quantitative measurement of the loss of ligand binding ability as described previously. 54, 55 Our data demonstrate that the more active conformations are less stable and denature at lower temperatures (the apparent T m ). In addition, the good correlation between receptor stability and activity, and the pattern of agonist and inverse agonist affinity for each receptor suggests that the stability change observed is not merely due to the point mutation per se. Rather it is due to global conformational changes involving multiple TMs (TMs 2, 3, 5, and 6) stemming from differential salt-bridge patterns. This is consistent with the predicted structures for those receptors with mutations in TMs 2 and 3. The observation that the inactive single mutant T3.46A is much more stable than the wild-type receptor strongly indicates that structural changes resulting from this single mutation are sufficiently substantial to provide enhanced stability of the mutant receptor; this is consistent with the changes observed in the predicted structures.
Intriguingly, although two inactive mutant receptors, D2.63A/L3.43A and T3.46A displayed a significant increase in GTPγS binding with 1 μM CP55940 treatment, the levels were substantially lower than that of the wild-type [ Fig. 3(B) ]. This may suggest that these inactive mutants can only partially mimic the activated conformations upon agonist binding. Perhaps ligand-induced full activation is not possible due to their lack of interactions critical for full receptor activation or else the existence of remaining constraints that stabilize the inactive state even upon CP55940 binding. Moreover, treatment with even higher concentrations of CP55940 (10 μM) failed to show any further increase in GTPγS binding (data not shown), suggesting that reduced affinity of the agonist for those receptors is not the underlying cause of the partial increase of CP55940-induced GTPγS binding observed. In contrast, all other constitutively active receptors (L3.43A/T3.46I, T3.46I, L3.43A, L3.43A/ T3.46A, wild-type, R2.37Q/T3.46A, and R2.37A/T3.46A) exhibited a similar level of maximum GTPγS binding with 1 μM CP55940 treatment. This data suggest that CP55940 induces a comparable conformation in the highly active mutant receptors (T3.46I and L3.43A). It would be interesting to further investigate how CP55940 docking alters the key salt-bridge pattern using the mutant receptors possessing different levels of constitutive activity.
In addition to experimentally testing structural predictions, this study permitted experimental testing of the extended ternary complex and related models with respect to agonist and inverse agonist affinity shifts. 2, 92, 93 Using the wide activity range of CB1 receptors evaluated here, we have for the first time demonstrated that the activity hierarchy of these receptors is consistent with their ligand binding profile: the highly constitutive active receptor exhibits an increased affinity for agonist but decreased affinity for inverse agonist; the fully inactive receptor exhibits the reverse; and the partially active receptors display intermediate profiles. These CB1 receptors provide a powerful framework for understanding the molecular basis for the multiple stages of receptor activation. These receptors also provide a good tool to screen for novel inverse agonists or partial agonists, which can selectively target receptors at different levels of activation. Thermal stability of the CB1 wild-type and mutant receptors. The membrane prepared from HEK293 cells expressing the wild-type or mutant receptors was incubated at the indicated temperature for 30 minutes followed by cooling on ice as described in Materials and Methods. The residual binding capacity after heating the receptor relative to control was measured using 
